[Low diuretic dosage in a beta blocker-diuretic combination]

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Therapeutics

Background:

• Arterial hypertension is a significant global health concern requiring effective management.
• Combination therapies are often employed to achieve better blood pressure control.

Purpose of the Study:

• To evaluate the efficacy and tolerability of Cardiotensin in treating outpatients with arterial hypertension.
• To assess the impact of Cardiotensin on blood pressure, heart rate response to stress, and key biochemical parameters.

Main Methods:

• A prospective study involving 30 outpatients with arterial hypertension.
• An eight-week treatment period with a daily dose of Cardiotensin (100mg bupranolol, 10mg bemetizide, 20mg triamterene) after a one-week placebo washout.
• Blood pressure monitoring, ergometer stress testing, and analysis of serum potassium, uric acid, creatinine, and glucose levels.

Main Results:

• Twenty-six out of 30 patients achieved normal blood pressure levels within two weeks.
• Significant reductions in blood pressure and heart rate elevations during ergometer stress testing were observed.
• No significant changes in serum potassium, uric acid, creatinine, or glucose concentrations were noted.
• Cardiotensin demonstrated good overall tolerability.

Conclusions:

• Cardiotensin is an effective and well-tolerated treatment for arterial hypertension.
• The combination therapy normalizes blood pressure in a majority of patients and mitigates abnormal cardiovascular responses to stress.
• It offers a favorable biochemical profile without adverse effects on electrolytes or metabolic markers.